- 1 Profiling pre-symptomatic and asymptomatic cases with confirmed SARS-CoV-
- 2 2 infection in Mexico City
- 3 Omar Yaxmehen Bello-Chavolla MD, PhD1*, Neftali Eduardo Antonio-Villa MD2, Arsenio
- 4 Vargas-Vázquez², Carlos A. Fermín-Martínez², Alejandro Márquez-Salinas², Jessica Paola
- 5 Bahena-López MD²

9

- ¹Division of Research, Instituto Nacional de Geriatría. ²MD/PhD (PECEM), Faculty of
- 8 Medicine, National Autonomous University of Mexico.
- 10 Short title: Asymptomatic SARS-CoV-2 in Mexico City
- 12 Corresponding author
- 13 Omar Yaxmehen Bello-Chavolla. Division of Research. Instituto Nacional Geriatría. Anillo
- 14 Perif. 2767, San Jerónimo Lídice, La Magdalena Contreras, 10200, Mexico City, Mexico.
- 15 Phone: +52 (55) 5548486885. E-mail: oyaxbell@yahoo.com.mx
- 16 **CONFLICT OF INTERESTS:** Nothing to disclose.
- 17 **FUNDING:** This research received no specific funding
- Word count: 1,198 words; 2 Figures, 1 Table.

ABSTRACT (295 WORDS)

- 20 **IMPORTANCE**: Asymptomatic SARS-CoV-2 infections are potential sources for transmission;
- 21 characterization of these cases has not been conducted in most low/middle income countries.
- 22 including Mexico.

- OBJECTIVE: To profile pre-symptomatic/asymptomatic SARS-CoV-2 infections in Mexico
- 24 City, its associated comorbidities and outcomes.
- 25 **DESIGN:** Prospective observational study
- 26 **SETTING:** Subjects assessed by convenience sampling within the National Epidemiological
- 27 Surveillance System in Mexico City.
- 28 **PARTICIPANTS:** Subjects with and without respiratory and non-respiratory symptoms (RS,
- NRS, respectively) assessed for SARS-CoV-2 using real time RT-PCR from nasopharyngeal
- 30 swabs.
- 31 **OUTCOMES:** Severe COVID-19, intensive care unit admission, 30-day mortality and their
- outcomes in cases RS or NRS and asymptomatic cases.
- 33 **RESULTS:** Amongst 60121 cases with confirmed SARS-CoV-2 infection as of July 1st, 2020,
- we identified 5982 cases without RS (9.9%) and 2452 who were asymptomatic at first
- evaluation (4.1%). Compared to cases with RS, NRS and asymptomatic cases were younger
- and had lower rates of comorbidities. Cases with NRS had higher rates of severe COVID-19
- 37 outcomes including hospitalization, ICU admission, and intubation (p<0.001). Mortality was
- 38 higher for cases with NRS (HR 3.13, 95%CI 1.80-5.45) or RS (HR 7.58, 95%CI 4.56-12.58)
- 39 compared to asymptomatic cases, adjusted for age, sex and comorbidities. Predictors for
- 40 mortality in cases without RS included older age, previous exposure to suspected viral
- 41 infection cases, comorbidities, presence of NRS and vomiting. For asymptomatic SARS-Co-
- 42 V-2 infections, chronic kidney disease, previous exposure with suspected infection cases and
- 43 older age were predictors for lethality.

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

CONCLUSIONS AND RELEVANCE: Definition of pre-symptomatic/asymptomatic cases has relevant implications for SARS-CoV-2 infection outcomes. Older age and comorbidity impact on the probability of developing severe complications for cases who were asymptomatic or had only NRS at evaluation and were sent for domiciliary treatment. Extending testing for detection of asymptomatic cases must be considered in Mexico to better understand the impact of the pandemic. Keywords: SARS-CoV-2; Asymptomatic; Pre-symptomatic; Mexico; COVID-19 outcomes **KEY POINTS** Question: What are the profiles and outcomes of pre-symptomatic/asymptomatic cases of SARS-CoV-2 infection in Mexico City? Findings: In this prospective observational study, we identified that cases with SARS-CoV-2 infection who were asymptomatic/pre-symptomatic at initial evaluation were younger with low rates of comorbidities, had higher rates of previous viral exposure or were healthcare workers. Compared to asymptomatic cases at first evaluation, cases with non-respiratory symptoms had higher risk of severe COVID-19 outcomes. Predictors for mortality in nonrespiratory or asymptomatic cases included non-respiratory symptoms, comorbidity and older age. Meaning: Definition of pre-symptomatic/asymptomatic cases has relevant implications for outcomes related to SARS-CoV-2 infections.

BACKGROUND

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

Asymptomatic infections are a potential source of rapid SARS-CoV-2 spread [1]. Prevalence of pre-symptomatic/asymptomatic cases varies widely but might represent a larger proportion of cases than previously anticipated [2]. Controversies surrounding asymptomatic SARS-CoV-2 infections have focused on the distinction between pre-symptomatic and asymptomatic infection and its definitions, which have focused on respiratory symptoms (RS), primarily cough, dyspnea and fever. Nevertheless, longitudinal data shows that only a fraction of initially asymptomatic infections develop subsequent symptoms [3-5]. In Mexico, SARS-CoV-2 testing focuses on sampling high-risk cases, which allowed characterization of increased susceptibility for severe COVID-19 attributable to cardio-metabolic comorbidities [6]; however, no data has been reported on asymptomatic SARS-CoV-2 infections. Lack of information regarding pre-symptomatic/asymptomatic cases in Mexico is concerning. particularly since many studies suggest that contact tracing of asymptomatic infections will be further SARS-CoV-2 spread [7]. pivotal to contain Here, we profile symptomatic/asymptomatic cases of SARS-CoV-2 infections to assess outcomes depending on its definitions using cases detected in Mexico City.

METHODS

We analyzed data from the National Epidemiological Surveillance System in Mexico City, an open-source dataset comprising daily updated cases tested using real-time RT-PCR to confirm SARS-CoV-2 using nasopharyngeal swabs according to the Berlin Protocol [8]. RS included fever, dyspnea, cough, polypnea or cyanosis at initial evaluation, whilst non-RS (NRS) included headache, myalgias, arthralgias, general malaise, abdominal pain, chest pain, conjunctivitis, irritability or vomiting. We defined cases with RS+NRS with ≥1 RS and any or none NRS. Cases with NRS had ≥1 NRS without RS, whilst asymptomatic cases had no symptoms. Pre-symptomatic cases were asymptomatic at admission but developed symptoms or required hospital admission after follow-up. To contrast definitions of pre-

symptomatic/asymptomatic cases based on RS, we combined asymptomatic and NRS cases and referred to them as cases without RS (WoRS). We confirmed these definitions using corresponding analyses; these results and available variables are detailed in **Supplementary Material**. Follow-up was conducted for all non-hospitalized cases up to 14 days; outcomes for all patients included hospital discharge due to clinical improvement or voluntary, ambulatory/treatment follow-up or death. NRS and asymptomatic cases were assessed outside the established framework for suspected COVID-19 cases in Mexico by convenience sampling and contact tracing. To evaluate predictors of RS+NRS and NRS we fitted a mixed effects logistic regression model, including facility of treatment as a random effect to account for the variability in case distribution and treatment across healthcare facilities. We calculated time-to-event for hospital admission and lethality for each group and modeled these outcomes using mixed-effects Cox Proportional Risk regression, including as a frailty penalty treatment facility. All statistical analyses were performed using R version 3.6.4.

RESULTS

Profiling pre-symptomatic/asymptomatic cases with SARS-CoV-2 infection

As of July 1st, 2020, 155722 subjects were tested for SARS-CoV-2. From 60121 cases with confirmed SARS-CoV-2 infection, 5982 cases were WoRS (9.9%). Amongst them, 3530 only had NRS (5.9%) and 2452 were pre-symptomatic/asymptomatic (4.1%). Cases WoRS and pre-symptomatic/asymptomatic were younger and had lower prevalence of NRS compared to cases with RS+NRS (**Figure 1**). Amongst cases WoRS (n=5982), 322 subjects were hospitalized (5.4%), 21 required mechanical ventilatory support (MVS) (0.4%), 36 required intensive care unit (ICU) admission (0.6%). Overall, 91 patients died (1.5%), of whom 25 were ambulatory and 66 hospitalized. Predictors for hospital admission included vomiting, abdominal pain, conjunctivitis, rhinorrhea, cardiovascular disease, immunosuppression, diabetes, hypertension, previous exposure to suspected viral cases and healthcare workers. Independent predictors of mortality in WoRS included older age, diabetes, chronic obstructive

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

pulmonary disease (COPD), chronic kidney disease (CKD), previous exposure to suspected viral cases, any NRS and, particularly, vomiting (**Supplementary Material**). As of July 1st, 4361 patients were still under domiciliary surveillance, 177 remained hospitalized, 78 were discharged after recovery, 1 had voluntary discharge and 1274 had completed domiciliary surveillance without developing RS. Amongst asymptomatic patients at first assessment (n=2431), 99 were hospitalized (4.0%), three required MVS (0.1%) and 19 required ICU admission (0.8%). We recorded 15 deaths (0.5%) amongst whom six were ambulatory and nine were hospitalized (Table 1). Predictors for hospital admission included younger age, cardiovascular disease, immunosuppression and previous exposure to suspected viral cases, whilst predictors of lethality included age >60 years, previous exposure to suspected viral cases, and immunosuppression. Currently, 1794 patients were still under domiciliary surveillance, 68 remained hospitalized, 22 were discharged after recovery, and 553 had completed follow-up without developing symptoms. Predictors and outcomes for RS+NRS, NRS and asymptomatic cases Presence of NRS was associated with younger age, healthcare workers, previous viral exposure, diabetes, obesity, female sex, hypertension and smoking, whilst RS+NRS were additionally associated with asthma and COPD, older age and male sex. Compared to presymptomatic/asymptomatic cases, risk of hospital admission was not significantly higher for NRS, but it was for RS+NRS (HR 2.71, 95%Cl 2.23-3.31), adjusted for age, sex and comorbidities. NRS and RS+NRS had higher mortality compared to asymptomatic cases (logrank p<0.001, Figure 2); adjusting for age, sex and comorbidities, NRS (HR 3.13, 95%CI 1.80-5.45) or RS+NRS cases (HR 7.58, 95%CI 4.56-12.58) retained higher mortality compared to asymptomatic cases. DISCUSSION Here, we present a comprehensive report of pre-symptomatic/asymptomatic COVID-19 cases in Mexico City. We show that the definition of asymptomatic SARS-CoV-2 infection should be

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

extended beyond RS to identify subjects at lowest risk of subsequent complications for domiciliary treatment who might contribute to further SARS-CoV-2 spread. We also report a low prevalence of pre-symptomatic cases amongst those who were initially classified as asymptomatic but eventually were hospitalized or had outcomes related to severe COVID-19 [9]. This data confirms observations from other populations and highlights the relevance of identifying pre-symptomatic/asymptomatic cases, given conflicting evidence on viral shedding for pre-symptomatic/asymptomatic cases, and data suggesting evidence of subclinical lung abnormalities which must be assessed longitudinally to rule out long-term impacts of SARS-CoV-2 infection [10]. Notably, a consistent predictor of outcomes for NRS cases and presymptomatic/asymptomatic cases are previous exposure to suspected viral cases, highlighting the relevance of contact tracing. Studies assessing natural history of asymptomatic SARS-CoV-2 infections highlighted the role of age and comorbidity in the subsequent development of symptoms, which is consistent with our observations [11]. Domiciliary surveillance in Mexico City focused on outcomes but not individual symptom onset, which might limit our ability to identify all pre-symptomatic cases. Regardless, only a small fraction of pre-symptomatic cases developed severe COVID-19 after being initially determined as asymptomatic, most of whom had underlying cardiometabolic comorbidities or were susceptible for complications of COVID-19 attributable to unmasked cardiometabolic comorbidities. Asymptomatic SARS-CoV-2 infections have been postulated to elicit lower immune responses and diminished antibody production compared to symptomatic cases. Severe COVID-19 in pre-symptomatic cases might be attributable to a combination of decreased early immune response to SARS-CoV-2 infection and late enhanced pro-inflammatory responses in subjects with comorbidities [10,12]. Here, we assessed a thorough constellation of symptoms in one of the largest studies of presymptomatic/asymptomatic SARS-CoV-2 infections. Limitations include non-assessment of atypical SARS-CoV-2 symptoms which might occur amongst otherwise asymptomatic cases,

particularly in older adults [13], and the lack of systematized sampling, which does not allow for an accurate estimation of asymptomatic cases in Mexico City. Our results highlight the need to systematize definition of asymptomatic cases and extend testing by contact tracing to detect asymptomatic SARS-CoV-2 infections as one of the mitigations strategies to reduce transmission of SARS-CoV-2 in Mexico City [14]. **ACKNOWLEDGMENTS**

170

171

172

173

174

175

176

177

178

179

180

181

185

- NEAV, JPBL, and AVV are enrolled at the PECEM program of the Faculty of Medicine at UNAM. JPBL and AVV are supported by CONACyT. The authors would like to acknowledge the invaluable work of all of Mexico's healthcare community in managing the COVID-19 epidemic. Its participation in the COVID-19 surveillance program has made this work a reality, we are thankful for your effort.
- 182 **DATA AVAILABILITY**
- 183 All data sources and R code are available for reproducibility of results at
- 184 https://github.com/oyaxbell/covid asymptomatic cdmx.

AUTHOR CONTRIBUTIONS

- Research idea and study design OYBC, NEAV, AVV, JPBL, CAFM, AMS; data acquisition: 186
- OYBC; data analysis/interpretation: OYBC, JPBL, NEAV, AVV, CAFM, AMS; statistical 187
- 188 analysis: OYBC; manuscript drafting: OYBC, NEAV, AVV, JPBL, CAFM, AMS; supervision or
- mentorship: OYBC. Each author contributed important intellectual content during manuscript 189
- 190 drafting or revision and accepts accountability for the overall work by ensuring that questions
- 191 about the accuracy or integrity of any portion of the work are appropriately investigated and
- 192 resolved.

- 193 **FUNDING:** No funding was received.
- 194 **CONFLICT OF INTEREST/FINANCIAL DISCLOSURE:** Nothing to disclose.

REFERENCES

- 197 1. Buitrago-Garcia DC, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Salanti G, et al.
- The role of asymptomatic SARS-CoV-2 infections: rapid living systematic review and
- meta-analysis. medRxiv. 2020; doi:10.1101/2020.04.25.20079103
- 200 2. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative
- 201 Review. Ann Intern Med. 2020; doi:10.7326/M20-3012
- 3. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al.
- 203 Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility.
- N Engl J Med. 2020;382: 2081–2090. doi:10.1056/NEJMoa2008457
- 205 4. Sakurai A, Sasaki T, Kato S, Hayashi M, Tsuzuki S-I, Ishihara T, et al. Natural History of
- Asymptomatic SARS-CoV-2 Infection. N Engl J Med. 2020;
- 207 doi:10.1056/NEJMc2013020
- 5. Imperial College COVID-19 Response Team, Lavezzo E, Franchin E, Ciavarella C,
- 209 Cuomo-Dannenburg G, Barzon L, et al. Suppression of a SARS-CoV-2 outbreak in the
- 210 Italian municipality of Vo. Nature. 2020; doi:10.1038/s41586-020-2488-1
- 211 6. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A, González-
- 212 Díaz A, Márquez-Salinas A, et al. Predicting mortality due to SARS-CoV-2: A
- 213 mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. J
- Clin Endocrinol Metab. 2020; doi:10.1210/clinem/dgaa346
- 215 7. Huff HV, Singh A. Asymptomatic transmission during the COVID-19 pandemic and
- implications for public health strategies. Clin Infect Dis. 2020; doi:10.1093/cid/ciaa654
- 217 8. Covid-19 SINAVE Ciudad de México Datos CDMX [Internet]. [cited 28 Jun 2020].
- 218 Available: https://datos.cdmx.gob.mx/explore/dataset/base-covid-sinave/table/
- 219 9. Meng H, Xiong R, He R, Lin W, Hao B, Zhang L, et al. CT imaging and clinical course of
- asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. J Infect.
- 221 2020;81: e33–e39. doi:10.1016/j.jinf.2020.04.004

222 10. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and immunological 223 assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 224 doi:10.1038/s41591-020-0965-6 225 11. [2006.08471] Probability of symptoms and critical disease after SARS-CoV-2 infection 226 [Internet]. [cited 28 Jun 2020]. Available: https://arxiv.org/abs/2006.08471 227 12. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen M-C, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in 228 COVID-19. Allergy. 2020; doi:10.1111/all.14364 229 230 Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, et al. 231 Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-232 wide surveillance study. The Lancet Psychiatry. 2020; doi:10.1016/S2215-233 0366(20)30287-X 234 Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles' Heel of 14. 235 Current Strategies to Control Covid-19. N Engl J Med. 2020;382: 2158–2160. 236 doi:10.1056/NEJMe2009758

Table 1. Descriptive characteristics of symptomatic and asymptomatic SARS-CoV-2 cases in Mexico City. *Abbreviations*: COPD: Chronic obstructive pulmonary disease; HIV/AIDS: Human immunodeficiency virus and/or acquired immunodeficiency syndrome; CKD: Chronic kidney disease, CDV: Cardiovascular disease; HCW: Healthcare worker

239

Parameter	RS+NRS (n=54139)	NRS (n=3530)	Pre-asymptomaticAsymptomatic (n=2452)	P-value
Age (years)	46.29±16.21	41.62±15.77	41.93±18.13	<0.001
Mortality (%)	6736 (12.4)	76 (2.2)	15 (0.6)	<0.001
Hospitalizacion (%)	15896 (29.4)	223 (6.3)	99 (4.0)	<0.001
ICU admission (%)	1368 (2.5)	17 (0.5)	19 (0.8)	<0.001
Mechanical-Ventilation (%)	2132 (3.9)	18 (0.5)	3 (0.1)	<0.001
Previous viral exposure (%)	20591 (38.0)	1936 (54.8)	1435 (58.5)	<0.001
Diabetes (%)	8467 (15.6)	331 (9.4)	138 (5.6)	<0.001
COPD (%)	898 (1.7)	23 (0.7)	15 (0.6)	<0.001

Asthma (%)	1309 (2.4)	70 (2.0)	33 (1.3)	<0.001
HIV/AIDS (%)	251 (0.5)	13 (0.4)	3 (0.1)	0.036
Obesity (%)	11083 (20.5)	538 (15.2)	201 (8.2)	<0.001
Smoking status (%)	5737 (10.6)	395 (11.2)	166 (6.77)	<0.001
CVD (%)	1336 (2.5)	58 (1.6)	30 (1.2)	<0.001
Hypertension (%)	10133 (18.7)	422 (12.0)	182 (7.4)	<0.001
Immunosupression (%)	885 (1.6)	39 (1.1)	31 (1.3)	0.022
CKD (%)	1077 (2.0)	38 (1.1)	16 (0.7)	<0.001
Healthcare worker (%)	9733 (18.0)	849 (24.1)	343 (14.0)	<0.001

FIGURE LEGENDS




FIGURE 1. Histogram comparing case distribution according to age groups comparing cases with RS+NRS, NRS and asymptomatic SARS-CoV-2 infection, demonstrating the role of age in determining asymptomatic SARS-CoV-2 infections (A). We also show a comparison of the distribution of NRS related to SARS-CoV-2 infections in subjects with RS+NRS and NRS only.

Abbreviations: RS: Respiratory symptoms; NRS: Non-respiratory Symptoms; Sudden onset: Patient report of sudden onset of symptomatology.




FIGURE 2. Factors associated with presence of RS+NRS compared to WoRS (NRS + Asymptomatic), and NRS compared to asymptomatic cases (NRS) with SARS-CoV-2 infection (A). We also show the and comparison of 30-day mortality rates between RS+NRS cases, NRS and asymptomatic SARS-CoV-2 infections in Mexico City.

Abbreviations: RS: Respiratory symptoms; NRS: Non-respiratory Symptoms; COPD: Chronic obstructive pulmonary disease; CKD: Chronic kidney disease; HCW: Health-care workers; Previous viral exposure: Prior contact with a patient with suspected viral infection.